Heidelberg, Germany – FundaMental Pharma GmbH, a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802. The study provides seminal preclinical proof-of-concept data...
Latest News
SAINT JOHN – With a pile of wet suds and some dirty cars, a collision repair shop hopes to set a Guinness World Record and help find a cure for cystic fibrosis. King CarStar Collision, on Rothesay Avenue, will join 80 other franchise locations in a national car wash Saturday...
A golf tournament and banquet Saturday will memorialize a former University of Oklahoma student and benefit a scholarship named in his honor. Events in A Servant’s Heart Weekend are in memory of William “Billy” Khourie II. The 22-year-old died Jan. 6 from a head injury he sustained while snowboarding in...
The Sabo family of Rutherford will host its third-annual Fragile X benefit at Yogi Berra Stadium in Montclair Thursday, June 25. The benefit will begin with a barbecue at 6 p.m. Then at 7:05 p.m., the New Jersey Jackals will take on the Worcester Tornadoes. Tickets for the baseball game...
A fundraiser will be held Thursday for Zachary Ghazali, a 17-year-old LaSalle boy who travels to China for medical treatment of a rare and terminal genetic disorder that attacks the immune system. Ghazali suffers from the incurable Friedreich’s ataxia, which progressively sabotages the co-ordination of the arms and legs, diminishes...
Canberra, Australia – A protein in the immune system programmed to protect the body from fungal infections is also responsible for exacerbating the severity of certain autoimmune diseases such as irritable bowel disease (IBS), type 1 diabetes, eczema and other chronic disorders, new research from The Australian National University (ANU)...
MISSOULA, Mont.— FYR Bio (“FYR”), a leader in liquid-biopsy precision medicine for neuro-oncology, today announced a collaboration with NuvOx Therapeutics, Inc. (“NuvOx”) supported by a two-year $1,976,897 Direct-to-Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI). The grant, titled “Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an...
RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the independent Data Monitoring Committee (DMC) recommended continuation of the pivotal Phase 3 trial (PRESERVE 2), evaluating trilaciclib in combination with gemcitabine and carboplatin for the first line treatment of metastatic triple negative...
Reston, VA — PET imaging with 68Ga-FAPI can more effectively detect and stage pancreatic cancer as compared with 18F-FDG imaging or contrast-enhanced CT, according to new research published in the December issue of The Journal of Nuclear Medicine. In a head-to-head study, 68Ga-FAPI detected more pancreatic tumors on a per-lesion, per-patient, or per-region...
Gabbie Strauss will slowly die from the inside out if a cure for an extremely rare disease can’t be found. The 19-month-old infant may look the picture of perfect health, but sadly that’s not the case. Gabbie is suffering from cystinosis, an incurable metabolic disease where the amino acid cystine...